HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Angelalign Technology (6699.HK) - Profit Margin Will Continue to Be Under Pressure

GSK Inks Eye-Popping $2B-Plus Pact for Hansoh’s ADC - Is The "New Story" About to Begin?

China Healthcare Weekly (Oct.27) - TCM Formula Granules VBP, Medical Statistics to Watch, Livzon

Angelalign Technology (6699.HK) 22H1 - Still “Bubble” in Valuation; The Era of High Margin Is Over

Angelalign Technology (6699.HK) - About the Share Price Rebound, the Outlook and the Challenges

Topchoice Medical (600763.CH) - The “True Secret” of Success and the Lost Luck

Gravity Works As WeWork Doesn't; Now Plan B

Equity Bottom-Up

Angelalign Technology  / Equity Bottom-Up

<ul>
<li>Angelalign’s business model is easily challenged by lower priced similar competing products. Once Angelalign’s products lose price advantage, it would lead to a rapid decline in overall sales performance. </li>
<li>Performance growth could still be under pressure this year due to unsatisfactory demand.The potential price war, further price reduction and increasing selling/marketing expenses would put more pressure on profit margin.</li>
<li>Angelalign hasn’t accumulated enough data size due to few overseas customers, which could lead to product quality issues and slow internationalization progress. There is downside risk due to overvaluation.</li>
</ul>


Angelalign’s business model is easily challenged by lower priced similar competing products. Once Angelalign’s products lose price advantage, it would lead to a rapid decline in overall sales performance. 
Performance growth could still be under pressure this year due to unsatisfactory demand.The potential price war, further price reduction and increasing selling/marketing expenses would put more pressure on profit margin.
Angelalign hasn’t accumulated enough data size due to few overseas customers, which could lead to product quality issues and slow internationalization progress. There is downside risk due to overvaluation.


Angelalign Technology (6699.HK) - 2023 May Not See a Turnaround in Performance